Duligotuzumab: Difference between revisions
CSV import Tag: Reverted |
No edit summary Tag: Manual revert |
||
| Line 27: | Line 27: | ||
{{No image}} | {{No image}} | ||
{{No image}} | {{No image}} | ||
Latest revision as of 17:20, 18 March 2025
Duligotuzumab is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Merck KGaA and ImClone Systems.
Mechanism of Action[edit]
Duligotuzumab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor 2 (HER2). By binding to these receptors, duligotuzumab inhibits the growth and proliferation of cancer cells that overexpress these receptors.
Clinical Trials[edit]
Duligotuzumab has been studied in clinical trials for the treatment of various types of cancer, including head and neck cancer, colorectal cancer, and non-small cell lung cancer. However, the results of these trials have been mixed, and the drug is not currently approved for use in any country.
Side Effects[edit]
Like all drugs, duligotuzumab can cause side effects. The most common side effects reported in clinical trials include fatigue, nausea, diarrhea, and skin rash. In some cases, these side effects can be severe and may require medical attention.
